Daniel C. Gibbons
YOU?
Author Swipe
View article: Treatment patterns and burden of uncomplicated urinary tract infection in England: a retrospective cohort study
Treatment patterns and burden of uncomplicated urinary tract infection in England: a retrospective cohort study Open
Background Uncomplicated urinary tract infections (uUTIs) are common bacterial infections. Aim To evaluate the burden of uUTI in England for 1) potential determinants of disease progression; 2) extent and impact of antimicrobial prescribin…
View article: Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records
Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records Open
Background To describe outcomes of high-risk patients with coronavirus disease 2019 (COVID-19) treated with sotrovimab, other monoclonal antibodies (mAbs), or antivirals, and patients who did not receive early COVID-19 treatment. We also e…
View article: Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment: a retrospective cohort study
Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment: a retrospective cohort study Open
Background The clinical benefit of coronavirus disease 2019 (COVID-19) treatments against new circulating variants remains unclear. We sought to describe characteristics and clinical outcomes of highest risk patients with COVID-19 receivin…
View article: Characteristics and outcomes of patients treated with sotrovimab to prevent progression to severe COVID-19 in Belgium
Characteristics and outcomes of patients treated with sotrovimab to prevent progression to severe COVID-19 in Belgium Open
This study indicated low rates of COVID-19-related hospitalisations and all-cause deaths in sotrovimab-treated patients in Belgium, including during Omicron subvariant periods, despite over two-thirds of the study population being immunoco…
View article: Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England
Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England Open
Background The impact of the constantly evolving severe acute respiratory syndrome coronavirus 2 on the effectiveness of early coronavirus disease 2019 (COVID-19) treatments is unclear. Here, we report characteristics and acute clinical ou…
View article: Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature review
Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature review Open
View article: Comparative effectiveness of sotrovimab versus no treatment in non-hospitalised high-risk COVID-19 patients in north west London: a retrospective cohort study
Comparative effectiveness of sotrovimab versus no treatment in non-hospitalised high-risk COVID-19 patients in north west London: a retrospective cohort study Open
Background We assessed the effectiveness of sotrovimab vs no early COVID-19 treatment in highest-risk COVID-19 patients during Omicron predominance. Methods Retrospective cohort study using the Discover dataset in North West London. Includ…
View article: Effect of clinical decision support for severe hypercholesterolemia on low-density lipoprotein cholesterol levels
Effect of clinical decision support for severe hypercholesterolemia on low-density lipoprotein cholesterol levels Open
View article: Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C)
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C) Open
View article: Referee report. For: Comparison of clinical characteristics and outcomes between COVID-19 survivors and non-survivors: a retrospective observational study [version 2; peer review: 1 approved, 1 not approved]
Referee report. For: Comparison of clinical characteristics and outcomes between COVID-19 survivors and non-survivors: a retrospective observational study [version 2; peer review: 1 approved, 1 not approved] Open
View article: Characteristics and outcomes of patients treated with sotrovimab to prevent progression to severe COVID-19 in Belgium
Characteristics and outcomes of patients treated with sotrovimab to prevent progression to severe COVID-19 in Belgium Open
Background Sotrovimab, a dual-action, engineered human monoclonal antibody, has been demonstrated to significantly reduce the risk of hospitalization and death in high-risk patients with COVID-19. Here, we describe the real-world use of, a…
View article: Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature review
Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature review Open
Background Emerging SARS-CoV-2 variants have impacted the in vitro activity of sotrovimab, with variable fold changes in neutralization potency reported for Omicron BA.2 and subsequent variants. We performed a systematic literature review …
View article: 37 Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England: A retrospective cohort study
37 Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England: A retrospective cohort study Open
View article: 510. Real-world Effectiveness of Sotrovimab for COVID-19: Evidence from United States (US) Administrative Claims Data
510. Real-world Effectiveness of Sotrovimab for COVID-19: Evidence from United States (US) Administrative Claims Data Open
Background This study compared outcomes among COVID-19 patients (pts) treated with the monoclonal antibody (mAb) sotrovimab matched to untreated pts. Methods Administrative claims (Komodo Health) were used to identify pts (≥ 12 years) diag…
View article: Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review
Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review Open
View article: P17 Baseline characteristics, disease progression rates and risk factors among female patients with uncomplicated urinary tract infection in England
P17 Baseline characteristics, disease progression rates and risk factors among female patients with uncomplicated urinary tract infection in England Open
Background and Objectives Uncomplicated urinary tract infection (uUTI) is a common, usually community-acquired bacterial infection. Little is known about risk factors for disease progression (defined here as hospitalization for Escherichia…
View article: P19 Burden of illness and costs among female patients with uncomplicated urinary tract infection in England
P19 Burden of illness and costs among female patients with uncomplicated urinary tract infection in England Open
Background and Objectives Uncomplicated urinary tract infection (uUTI) is usually community-acquired. Data regarding the wider burden of illness from uUTI are scarce. We evaluated the burden of uUTI in female patients in England. Methods T…
View article: P18 Treatment patterns and extent of inappropriate antimicrobial treatment among female patients with uncomplicated urinary tract infection in England
P18 Treatment patterns and extent of inappropriate antimicrobial treatment among female patients with uncomplicated urinary tract infection in England Open
Background and Objectives Inappropriate antimicrobial treatment of uncomplicated urinary tract infection (uUTI) has potential impacts on healthcare resource use and costs. We characterized treatment patterns for uUTI in England, including …
View article: Comparative effectiveness of sotrovimab versus no treatment in non-hospitalised high-risk patients with COVID-19 in North West London: a retrospective cohort study using the Discover dataset
Comparative effectiveness of sotrovimab versus no treatment in non-hospitalised high-risk patients with COVID-19 in North West London: a retrospective cohort study using the Discover dataset Open
Introduction There is uncertainty regarding how in vitro antibody neutralisation activity translates to the clinical efficacy of sotrovimab against severe acute respiratory syndrome coronavirus 2, although real-world evidence has demonstra…
View article: Prevalent new user designs: A literature review of current implementation practice
Prevalent new user designs: A literature review of current implementation practice Open
Purpose Prevalent new user (PNU) designs extend the active comparator new user design by allowing for the inclusion of initiators of the study drug who were previously on a comparator treatment. We performed a literature review summarising…
View article: Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals or no treatment in Scotland
Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals or no treatment in Scotland Open
Introduction Severe acute respiratory syndrome coronavirus 2 is constantly evolving. The clinical benefit of coronavirus disease 2019 (COVID-19) treatments against new circulating variants remains unclear. We sought to describe the real-wo…
View article: CO103 Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the National COVID Cohort Collaborative (N3C)
CO103 Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the National COVID Cohort Collaborative (N3C) Open
View article: CO56 Real-World Effectiveness of Early Treatments for COVID-19: Evidence from Administrative Claims Data
CO56 Real-World Effectiveness of Early Treatments for COVID-19: Evidence from Administrative Claims Data Open
View article: Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review
Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review Open
Purpose Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have impacted the in vitro activity of sotrovimab 500 mg, with reduced fold change in EC 50 for the Omicron BA.2 sublineage and onward. The correlation …
View article: Characteristics and Outcomes of COVID-19 Patients Presumed to be Treated with Sotrovimab in NHS Hospitals in England
Characteristics and Outcomes of COVID-19 Patients Presumed to be Treated with Sotrovimab in NHS Hospitals in England Open
Introduction There is limited real-world evidence describing the effectiveness of early treatments for Coronavirus disease 2019 (COVID-19) during the period where Omicron was the dominant variant. Here we describe characteristics and acute…
View article: Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA Open
View article: EE468 Healthcare Resource Utilisation and Costs Associated With the Management of Hospitalised COVID-19 Patients in England
EE468 Healthcare Resource Utilisation and Costs Associated With the Management of Hospitalised COVID-19 Patients in England Open
View article: 1145. Real-world Effectiveness of Sotrovimab for the Early Treatment of COVID-19 in the US
1145. Real-world Effectiveness of Sotrovimab for the Early Treatment of COVID-19 in the US Open
Background Sotrovimab, a monoclonal antibody (mAb), received Emergency Use Authorization (EUA) for the treatment of high-risk outpatients with symptomatic COVID-19. The study objective was to evaluate real-world effectiveness of sotrovimab…
View article: Characteristics and outcomes of patients with COVID-19 at high-risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England
Characteristics and outcomes of patients with COVID-19 at high-risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England Open
Introduction There is limited real-world evidence surrounding the effectiveness of early, mild-to-moderate COVID-19 treatments following the emergence and dominance of Omicron SARS-CoV-2 subvariants. Here, characteristics and acute clinica…
View article: Treatment patterns, healthcare resource use, and costs associated with uncomplicated urinary tract infection among female patients in the United States
Treatment patterns, healthcare resource use, and costs associated with uncomplicated urinary tract infection among female patients in the United States Open
Background We evaluated associations between antibiotic prescription and healthcare resource use and costs (Part A), and between antibiotic switching and healthcare resource use, costs, and uncomplicated urinary tract infection recurrence …